Mounjaro vs. Wegovy: Which is Right for Your Biology?
The weight loss landscape in the UK has shifted. With the arrival of Mounjaro® (Tirzepatide) and Wegovy® (Semaglutide), we finally have tools that address the biological roots of obesity. But which one should you choose?
The Science of Satiety Wegovy is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a hormone your body naturally produces to tell your brain you are full.
Mounjaro is a "dual agonist." It mimics GLP-1, but also adds a second hormone called GIP (glucose-dependent insulinotropic polypeptide). In clinical trials, this dual-action approach showed slightly higher weight loss percentages—up to 22.5% over 72 weeks compared to Wegovy’s 15%.
Which is right for you? Choosing a medication isn't just about the numbers; it’s about side-effect management and how your body responds to the dosage. While Mounjaro often shows faster results, Wegovy has a longer track record of safety data in the UK.
The EverLean Perspective At EverLean, we believe the "pen" is only the hardware. Your biology is the operating system. Whether you choose Wegovy or Mounjaro, the medication provides a "quiet period" in your brain. Our job is to help you use that quiet period to install the Habit Architecture required to keep the weight off once the medication stops.
